This is a demo store. No orders will be fulfilled.

Cendakimab (anti-IL-13) - Primary antibody, specific to IL13, Human IgG1, INHIBITOR of Interleukin-13 inhibitor, INHIBITOR of Interleukin-13 inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab182808
Grouped product items
SKU Size
Availability
Price Qty
Ab182808-100μg
100μg
10
$69.90
Ab182808-1mg
1mg
4
$349.90
Ab182808-5mg
5mg
1
$899.90
Ab182808-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,439.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Cendakimab (anti-IL-13) - Primary antibody, specific to IL13, Human IgG1, INHIBITOR of Interleukin-13 inhibitor
Synonyms Allergic rhinitis antibody | ALRH antibody | BHR 1 antibody | BHR1 antibody | Bronchial hyperresponsiveness 1 (bronchial asthma) antibody | IL 13 antibody | IL-13 antibody | Il13 antibody | IL13_HUMAN antibody | Interleukin 13 antibody | interleukin13 ant
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity IL13
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of Interleukin-13 inhibitor
Product Description

Cendakimab (anti-IL-13) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab (anti-IL-13) has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab (anti-IL-13) recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab (anti-IL-13) has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.9 kDa (Light Chain) & 50.6 kDa (Heavy Chain), under reducing conditions; 202.3 kDa, under non-reducing conditions.
Purification Method Protein A purified
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 2151032-62-9

Associated Targets(Human)

IL13 Tclin Interleukin-13 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Cendakimab (anti-IL-13) (Ab182808) - ELISA
Immobilized IL-13-his at 2.0 μg/mL can bind Cendakimab (anti-IL-13) (Ab182808) with the EC50 of 2.081 ng/mL.

Cendakimab (anti-IL-13) (Ab182808) - SEC
The purity of Cendakimab (anti-IL-13) (Ab182808) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0607193 Certificate of Analysis Jun 21, 2024 Ab182808
ZJ24F0607192 Certificate of Analysis Jun 21, 2024 Ab182808
ZJ24F0607191 Certificate of Analysis Jun 21, 2024 Ab182808

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.